Certara Software Revenue Rises 11% to $48.8M
The drug development technology company reported software growth for the quarter ended Sept. 30, 2026, while narrowing its full-year revenue outlook.
Updated on Nov. 11, 2026 in Healthcare

Certara Inc. reported software revenue growth of 11% to $48.8 million for the quarter ended Sept. 30, 2026, compared with $43.8 million a year earlier. Total continuing operations revenue rose 4% to $94.9 million, though the company posted a net loss from continuing operations of $3.6 million, or 2 cents per diluted share.
Why it matters
The results reflect growth in software demand for drug development tools even as services revenue declined 2% to $46.1 million. The company's narrowed 2026 forecast and margin improvements offer insight into how it is reshaping its portfolio after divesting its Regulatory and Medical Writing business in May.
Software bookings rose 15% to $46.9 million while services bookings fell 5% to $45.6 million, and cash stood at $214.9 million at the end of September. The trailing 12-month services book-to-bill ratio was 1.15, on combined trailing bookings of $409.2 million.
The players
Certara Inc.
Certara is a Radnor, Pennsylvania-based drug development technology and biosimulation company that sells software and services to pharmaceutical and biotechnology firms.
Grant Peterson
Grant Peterson was appointed Certara's chief product officer, effective Nov. 2, 2026, overseeing the company's product strategy.
The details
Cost of revenue fell to $31.4 million from $33.4 million, while operating expenses rose to $61.1 million, driven largely by $4.4 million in additional employee-related costs. Management narrowed its full-year 2026 continuing-operations revenue growth forecast to 2% to 3% and maintained a fourth-quarter adjusted EBITDA margin outlook of 29% to 31%.
Timeline
May 8, 2026: Regulatory and Medical Writing business divested.
Sept. 30, 2026: Quarter ended with reported software and services results.
Nov. 2, 2026: Grant Peterson takes effect as chief product officer.
Market Landscape
Certara's May 2026 divestiture of its Regulatory and Medical Writing business moved the company further toward software, where revenue grew 11% this quarter. The results position it to compete on software bookings growth, which reached 15%, even as its services line contracted.
For drug developers and their partners, Certara's continued software growth signals sustained access to its modeling tools as the company narrows its revenue outlook. The results matter most to clients evaluating whether the company's services offerings will remain stable as its portfolio shifts toward software.
The takeaway
Software-led growth can offset services declines, as Certara's 11% software gain shows while its services revenue slipped 2%. Investors and clients should watch whether the company meets its narrowed 2026 forecast in the coming quarter.
Further reading
Explore more healthcare business news to see how drug development technology firms are adapting to shifting demand.
Source note: This article includes information reported by MyChesCo.






